Abstract Library

#4096 Co-production of patient information: A model for today’s practice

Introduction: According to the British Medical Association, good quality patient information is fundamental to effective, patient-centred, quality care. It rightly considers patients as partners in their care, “Co-production involves engaging groups of people who use healthcare services, in equal partnership; at the earliest stages of service design, development and evaluation. It acknowledges that people with ‘lived experience’ of a particular condition are often best placed to advise on what support and services will make a positive difference to their lives.” (NHS England) The re-introduction of a liver transplantation programme in the UK for selected patients with a Neuroendocrine Neoplasm offers new opportunities to improve survival and quality of life: good quality information is a key tool for informed consent.

Conference:

Presenting Author:

Authors: Jervis N, Ellis C, Smith S, Shah T, Lewis K,

Keywords: Liver Transplantation, Co-production, Patient Information, Lived Experience Contribution,

#3415 The PEI-Q paradox: Qualitative assessment of exocrine function in NET patients treated with SSAs

Introduction: Somatostatin-analogues (SSAs) are first-line treatment of unresectable, symptomatic neuroendocrine tumors (NETs), though can cause pancreatic exocrine insufficiency (PEI). PEI symptoms of diarrhoea, bloating, and steatorrhea overlap with those of NETs (carcinoid sequelae), and both have a negative impact on quality of life. The Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) can be used to assess PEI; however, we hypothesise that the score will be unreliable in SSA-induced PEI due to concurrent improvement of carcinoid symptoms.

Conference:

Presenting Author: Hall L

Authors: Hall L, Powell-Brett S, Thompson O, Bradley E, Smith S,

Keywords: Pancreatic Exocrine Insufficiency (PEI), Neuroendocrine Tumor (NET), Patient Reported Outcome,

#3156 To determine the true incidence of brain metastases in atypical lung neuroendocrine tumors and explore factors that increase the risk of intracranial disease

Introduction: Lung neuroendocrine tumors (NETs) make up 25% of all NETs. Typical carcinoid (TC) and atypical carcinoid (AC) account for 2% and 0.2% of all lung NETs respectively, and AC tend to be more aggressive. Although both can metastasise, AC are more likely; common sites include bone and liver. Currently, brain imaging is not included in the work-up of TC/AC, as

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Jones J, Spurgeon L, Shaheen F, Lewis A, Mansoor W,

Keywords: typical carcinoid, atypical carcinoid, brain metastases, Ki67,

#2254 Development of a Patient-Centred Service for Neuroendocrine Tumors (NETs) in Wales: Population Based National Commissioning

Introduction: Requiring many specialities and services, NETs have complex pathways presenting a challenge to plan services in existing NHS structures

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Khan M, Reynolds M, Lewis J, Bell C, Rees A,

Keywords: Service, commissioning, Mdt,

#1835 A Prospective Service Evaluation of Systematic Gastroenterological Assessment and Management on Patients with Neuroendocrine Tumours in South East Wales

Introduction: Patients with NETs can experience gastrointestinal(GI) symptoms including diarrhoea, steatorrhoea and urgency.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Donnelly L, Tailor S, Reid K, Williams M, Lewis J,

Keywords: Quality of life, Diarrhea,